A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis
CompletedNot applicableNCT00214695
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the inflow pain using an experimental peritoneal dialysis solution compared to a current solution for the management of end stage renal disease (ESRD) in peritoneal dialysis (PD) patients.
Study details
- Official title
- A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis
- Conditions
- End Stage Renal Disease
- Interventions
- Drug: Experimental Peritoneal Dialysis Solution
- Sponsor
- Vantive Health LLC
- Collaborators
- Baxter Healthcare Corporation
- Start date
- 2005-05
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Sweden
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with PD using specific solutions for at least 30 days before the screening visit. * Patients who experience pain on infusion based on medical judgement. Exclusion Criteria: * Patients who have received antibiotics for the treatment of an episode of peritonitis within 30 days before to screening visit. * Patients who have had acute or chronic exit-site or tunnel infection in the past 14 days, counted from the last day of infection to the screening visit. * Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted. * Patients who have received an investigational product within 30 days preceding the screening visit. * Patients who are pregnant or lactating. (NB: Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of the screening and will be required to use a medically acceptable means of contraception during their participation in this study). * Patients who have a significant psychiatric disorder or mental disability that could interfere with his/her ability to provide informed consent and/or comply with protocol procedures.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00214695